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Abstract
Background: Cognitive rehabilitation is a highly individualised, non-pharmacological intervention for people with
mild cognitive impairment (MCI) and dementia, which in recent years has also been developed for various IT
platforms.
Methods: In this study, we aim to evaluate the effectiveness of the cognitive rehabilitation software GRADIOR in a
multi-centre, single-blinded randomised controlled trial with people with MCI and mild dementia. A total of 400
people with MCI and mild dementia will be randomly allocated to one of four groups. This trial will compare the
cognitive rehabilitation treatment using the GRADIOR programme with a psychosocial stimulation intervention
(PSS) using the ehcoBUTLER platform, with a combined treatment consisting of GRADIOR and ehcoBUTLER, and
with a group receiving treatment as usual during a period of 1 year.
Discussion: The outcomes of this clinical trial will be to determine any relevant changes in cognition, mood,
quality of life, activities of daily living and quality of patient-carer relationship after 4 months and 1 year of
intervention in a cross-sectional group comparison. Participants will be followed-up for 1 year to investigate
potential long-term effects of the conducted treatments.
Trial registration: Current Controlled Trials ISRCTN, ID: 15742788. Registered on 12 June 2017.
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Background
Current prevalence rates of dementia in Spain are approxi-
mately 1.75% of the state population, which equates to
more than 800,000 people [1]. In their annual report, Alz-
heimer’s Disease International [2] estimate a prevalence of
1.6 million new cases of dementia per year in people over
60 years of age solely in Western European countries,
which is accompanied by increasing costs per capita each
year. Mild cognitive impairment (MCI) is a condition with
various subtypes of different progression and prognoses,
with 20–40% of cases progressing to dementia [3]. The
overall crude prevalence of MCI is estimated at around 6–
12% at the lower end, with some reviews reporting a preva-
lence rate of up to 42% in people over 60 years of age [4].
Progressive cognitive deficit, which is present in dementia,
restricts the individual independence and the activities of
daily living of every person affected [5, 6]. Moreover, it also
places high demands on caregivers, family members and
health professionals involved in their care [7]. For these
reasons, it is important to find a sustainable approach to
maintain the independence and self-efficacy of people with
dementia (PwD) and MCI. Importantly, cognitive interven-
tions seem to be beneficial not only for PwD, but also for
their caregivers [8].
Cognitive rehabilitation is a highly individualised inter-
vention specific to patients’ needs and goals [9], and in
people with mild dementia is used to improve or maintain
their cognitive status [10]. On the other hand, cognitive
trainings are focussed on training or restoration of one par-
ticular ability or skill (e.g. working memory, attention, etc.)
[11]. Cognitive rehabilitation has shown to be more effect-
ive than cognitive training or group reminiscence therapy,
having a positive effect on decreasing the functional de-
cline of PwD [12]. Similarly, a systematic review by Clare
and Woods reported no significant effects of cognitive
training interventions; while the only study on cognitive re-
habilitation included in the review found preliminary but
promising results of this approach when applied in people
with Alzheimer’s disease and vascular dementia [11]. Inten-
sive cognitive rehabilitation programmes can also reduce
behavioural disturbances in PwD [13], but their influence
on activities of daily living, quality of life or symptoms of
depression remains inconclusive [14]. Cognitive rehabilita-
tion can also significantly improve cognition, and reduce
behavioural disturbances and symptoms of depression in
MCI [15]. Furthermore, cognitive rehabilitation has been
proven to have a positive effect in caregivers of PwD by
lowering the feeling of burden and improving their confi-
dence in caregiving situations [16].
Computer-based cognitive interventions are a cost-
effective and flexible approach which are nowadays easily ac-
cessible to the public [17]. Computer-based cognitive train-
ings have shown to be efficient in people with MCI, which is
important when addressing Alzheimer’s disease prevention
or delaying the onset of the disease [18]. Currently, the field
of cognitive rehabilitation for people with MCI is relatively
underdeveloped in comparison to cognitive training. How-
ever, studies have shown that computer-based cognitive re-
habilitation can also improve general cognition [19], as well
as reduce depression and anxiety symptoms in MCI [20]. A
meta-analysis by García-Casal et al. [21] reported a signifi-
cant improvement in cognition, depression and anxiety in
PwD involved in computer-based cognitive interventions.
Furthermore, it has been reported that computer-based cog-
nitive rehabilitation is able to delay memory deterioration in
PwD [22]. People with dementia with low levels of func-
tion can also benefit from computer-based rehabilita-
tion programmes which can improve different cognitive
domains and mood [23]. Although a different meta-
analysis did not reveal any significant changes in cogni-
tion for PwD, more studies are necessary in order to
discover the potential long-term effects of computer-
based cognitive interventions in PwD [24].
Stimulating social activities can serve as an effective pre-
vention strategy in primary care, delaying cognitive deteri-
oration in older PwD and MCI [25]. Psychosocial
interventions can also introduce positive changes in cogni-
tion, mood or communication in PwD [26] and MCI [27].
GRADIOR is a computer-based programme used for
the neuropsychological rehabilitation of people with vari-
ous cognitive impairments of different aetiology, as well as
for cognitive stimulation of healthy individuals. GRA-
DIOR consists of dynamic exercises designed to stimulate
all cognitive abilities, offering tools to tailor the cognitive
intervention to each person according to their individual
needs. The programme also provides tools for the evalu-
ation of the current performance in every cognitive do-
main, which is important for treatment adjustments
(changing difficulty levels for each task independently ac-
cording to the participants’ performance).
The psychosocial stimulation platform ehcoBUTLER
was designed to improve the quality of life of older
people and their caregivers by promoting a healthy life-
style and stimulating active aging through the use of
tools that enhance positive emotions and cognitive train-
ing [28]. EhcoBUTLER contains leisure activities and
other activities focussed on care, and can be adjusted to
the needs of every person individually. The aim of all
activities is to reduce social isolation, cognitive and
physical inactivity and sedentary behaviours, and to pro-
mote health, satisfaction and personal wellbeing.
The platform has different versions. The leisure version
contains various applications including Wellbeing (Walk),
Internet, Book of Life, My Memories (photographs, music
and videos), Leisure Activities (books and puzzles) and So-
cial Applications (friends, mail and videoconference). The
care version adds activities to each module, such us Nutri-
tion and Lifestyle recommendations, which is part of the
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Wellbeing module. The platform also facilitates communi-
cation and can be used by families and caregivers with the
aim of sharing information and keeping up to date with
the daily activities or conditions of people. The platform
can be used in different devices such as PCs, touch-screen
computers and tablets.
Currently, despite the large number of different
computer-based cognitive rehabilitation programmes,
there is a lack of large-scale randomised controlled trials
(RCTs) on individualised cognitive rehabilitation pro-
grammes [12]. Furthermore, despite providing initially
promising results, the results on the effectiveness of cog-
nitive rehabilitation trainings are still inconclusive and
more RCTs are required in this area [29].
For this reason, we will conduct an interviewer-blinded,
multi-centre randomised controlled trial with four parallel
groups. The primary aim of which is to determine the ef-
fectiveness of the cognitive rehabilitation programme
GRADIOR and the psychosocial stimulation platform
ehcoBUTLER, separately or in a combined treatment, on
the cognition, quality of life, activities of daily living, rela-
tionships with carers and depressive symptoms of people
with MCI and PwD. Based on previous research, we hy-
pothesise that people with MCI and PwD in the cognitive
rehabilitation group using GRADIOR or combined treat-
ment will improve their cognition in comparison to other
treatment groups and/or the treatment as usual (TAU)
group. A secondary aim is to examine the interaction be-
tween psychosocial stimulation and cognitive rehabilita-
tion in order to discover their synergies or usefulness. The
duration of the RCT is 1 year of treatment followed by a
1-year follow-up study.
A preliminary study on the usability of GRADIOR and
ehcoBUTLER will be conducted through focus groups
and users’ testing in order to identify any issues in the
programme’s features which may potentially influence its
effectiveness in MCI and PwD. Additional data will be
collected and any incidents will be monitored to im-
prove the final usability of both programmes.
Methods
Design
This is a multi-centre, randomised controlled, interviewer-
blinded trial, with four parallel groups, 1:1:1:1 allocation ra-
tio. Potential participants will be identified by collaborating
professionals at recruitment sites and those interested in par-
ticipating will sign an informed consent form. Subsequently,
those selected based on inclusion/exclusion criteria (n= 400)
will undergo preliminary testing and will be randomly allo-
cated to one of the four study groups. In this study, there are
three intervention groups and one group receiving TAU.
Intervention groups are: (1) cognitive rehabilitation with the
GRADIOR programme (GRA), (2) a computer-based psy-
chosocial stimulation group (ehcoBUTLER) (PSS) and (3) a
group receiving a combined treatment of GRADIOR to-
gether with computer-based psychosocial stimulation (ehco-
BUTLER CARE) (COM). Primary and secondary measures
data will be collected at baseline, at 4 months after the start
of the treatment and at 12 months, immediately after com-
pleting the interventions. Follow-up assessments will be car-
ried out 4 and 12 months after finishing the treatment
(months 16 and 24 of the study). A preliminary study of us-
ability will be conducted before the start of the trial. The full
study timeline is described in Table 2.
Sample size
Maximal sample size for the study was set at 400 partici-
pants with dementia and MCI. We considered a 15%
dropout by participants during the 12 months of interven-
tions and 12 months of follow-up. Therefore, the final
sample size for the study is likely to be 340 participants.
Considering that the standard deviation of the selected
population in the selected variables of the study was un-
known and the population size was undetermined, we
opted for a calculation of the sample size for an infinite
population with the maximal level of variability of the
dependent variables of the study (p = q = .5). If the popu-
lation scattering parameters are unknown, this calcula-
tion allows for a more conservative sample size,
meaning the biggest sample size [30].
The calculation was executed using the following
equation (α = .05):
n ¼
Z2∝=
2
0:52
e2
;
where 0.52 is a maximal variability (p * (1 − p)), Z∞/2
corresponds to scores in the percentile α/2 (.025) of a
normal distribution, and e corresponds to the error
acquired for the desired sample size, with a result of
e = 5.3% for a sample size of 340 participants.
On the other hand, based on the Friedman table for de-
termining effect size [31], for the primary outcome meas-
ure ADASCog to achieve 80% power (alpha 0.05) on a
sample of 340 participants we are looking for an approxi-
mate effect size of 0.30, which is similar to a separate
study protocol on cognitive rehabilitation in PwD [9].
Participants
The initial identification of suitable participants with
MCI and mild dementia will take place at various sites
within the province of Zamora, Spain: community cen-
tres, memory clinics, public hospitals, daycare centres
and residential centres.
The inclusion criteria for participants with MCI and
mild dementia will be: aged over 60 years, possess the
capacity for making decisions, have a reference person
or a caregiver, and be able to read and write in
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Spanish. For those with a diagnosis of MCI, the study
will comply with the criteria of Petersen [32] and the
International Working Group (IWG) for people with
amnestic MCI [33], where participants should have a
Clinical Dementia Rating (CDR) score = .5 and Geriatric
Depression Scale (GDS) < 5. For those with a diagnosis of
dementia, participants should meet the Diagnostic and
Statistical Manual for Mental Disorders (DSM-5) diag-
nostic criteria for major neurocognitive disorders, CDR
score ≥ 1 and < 2 and GDS score < 5 [34].
The exclusion criteria for both groups will be: loss
of senses that make it difficult to use the devices
(blindness, deafness) or severe physical comorbidity (a
disease causing tremor), current significant neuro-
logical disease (e.g. Parkinson’s disease, Huntington’s
disease, Lewy-body dementia, epilepsy, multiple scler-
osis, traumatic brain injury, etc.), current significant
anxiety or depressive disorder (DSM-5 criteria) that would
affect cognitive functioning and thus act as confounders,
having a current history of alcoholism and/or substance
abuse (including alcohol-related dementia), or currently
taking any antipsychotic medications. All participants must
be willing to participate in the study voluntarily and will
sign an informed consent form. Some of the participants
may be taking anticholinesterase inhibitors or memantine.
These participants must have been stabilised on their
current dose for a minimum of 1 month prior to the base-
line assessment. This is to ensure that any changes will not
be confounded by medication effects. All inclusion/exclu-
sion criteria are summarised in Table 1.
An additional criterion will be MMSE score, defined by a
cut-off point of ≤ 27 points for MCI and 20 < x < 25 points
for people with mild dementia. The score of each partici-
pant in this test will be adjusted according to their age and
years of education based on the study by Blesa, Pujol and
Aguilar [35] as follows: (1) for participants between
51 and 75 years of age and 8 or less years of educa-
tion + 1 point, and − 1 point for more than 17 years
of education; (2) for participants over 75 years of age
and 8 or less years of education + 2 points, and + 1
point for 9–17 years of education.
Allocation and randomisation
Participants will be randomly allocated in a 1:1:1:1 ra-
tio to either of the four trial arms using a computer-
generated random number sequence. The Epidat 4.1
programme will be used to generate this sequence.
The allocation will be carried out by an independent
researcher who will be unaware of the characteristics
of the study. Participants will be allocated to each
group using simple randomisation. Simple randomisa-
tion will allocate every participant randomly in a
group independently of their characteristics (age, sex,
education, area, etc.).
Participants will agree to participate before the ran-
dom allocation takes place and without knowing to
which group they will be allocated. The staff member re-
sponsible for sequence generation will provide partici-
pants with the details of the treatment group that they
were allocated to independently from study coordina-
tors. Participants will receive a sealed envelope by post
with sufficient details and instructions about how to
start their participation in the treatment.
Procedure and intervention
Usability study
The techniques used to carry out the usability study will
be: focus group, users’ testing and usability questionnaires.
The usability study will consist of three different phases:
1. Pre-experimental phase
Focus group
Focus group of GRADIOR: this will be used to deter-
mine whether the experience of using the program is
adequate and if its interface is functional and intuitive
for people with MCI and mild dementia, as well as for
the healthcare professionals. The following participants
will be recruited: two groups with MCI, two groups with
mild dementia and two groups of professionals who have
experience with GRADIOR in PwD and/or MCI.
Focus group of ehcoBUTLER: this will be used to
determine whether the characteristics and tools of the
ehcoBUTLER platform, as well as its design, would be well
accepted by people with MCI and mild dementia, as well
as by relatives and professionals. Participants will be shown
a video about the programme and its tools. The following
participants will be recruited: two groups with MCI, two
groups with mild dementia, two groups of informal carers
or family members and two groups of professionals who
have worked or work with PwD and/or MCI.
The different focus groups of both GRADIOR and
ehcoBUTLER will consist of five to six people each. In
order to carry out focus groups, scripts with general and
specific open questions will be developed to obtain the
necessary information for the research. In addition, par-
ticipants will obtain an informed consent to record the
sessions in audio and video for later analysis.
Users’ testing
This will be carried out in a usability laboratory and users’
interactions with the GRADIOR and ehcoBUTLER pro-
grams will be recorded.
GRADIOR user test: five people with MCI, five with
mild dementia and five professionals will be recruited
who have no prior experience with GRADIOR.
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ehcoBUTLER user test: five people with MCI, five
people mild dementia and five professionals will be
recruited.
In both cases, the users will perform a series of practical
tasks in the GRADIOR and ehcoBUTLER programs.
Only one user at a time can perform the experi-
ment in order to establish a careful monitoring of
their actions and behaviour; measures of effectiveness,
efficiency and satisfaction. In addition, the session will
be recorded in audio and video for later analysis. All
participants should have some prior experience with
information and communication technology (ICT).
Before starting the tests, participants will be asked to
sign an informed consent. At the end of the assign-
ment the participants will have to complete the
System Usability Scale (SUS), which will serve to as-
sess the usability and satisfaction with the programs.
2. Experimental phase
During this phase, data in the RCT will be collected from
the participants using GRADIOR and/or ehcoBUTLER
about all the incidents that occurred with the GRADIOR
and ehcoBUTLER programs for further analysis. All the
incidents that arise during the treatment about technical
aspects and use of the program, referring to both the soft-
ware and hardware, will also be collected. These will be re-
ported on a record sheet. This data will be analysed and
will serve to assess the problems encountered by users and
the difficulties of implementing the program.
3. Post-experimental phase
Once the experiment is finished, the User Experience
Questionnaire (UEQ) will be administered, which will
serve to assess the participants’ user experience.
Intervention
Intervention sites will vary depending on accessibility
and mobility of participants. Community centres, social
care centres, memory clinics, community centres, resi-
dential care homes and similar facilities within the prov-
ince will participate in the study.
The first cognitive rehabilitation session with GRA-
DIOR will be used as a baseline which will help deter-
mine each participant’s level of ability. The baseline
treatment is a shorter version of the usual intervention
and includes exercises from various subdomains which
will determine the level of difficulty for the main treat-
ment and also help the participants to familiarise them-
selves with the programme and its interface. During the
first psychosocial stimulation session with ehcoBUTLER,
a member of staff will create a user profile for each par-
ticipant and demonstrate how to use the platform.
GRADIOR: Computer-based cognitive rehabilitation (GRA)
GRADIOR is a neuropsychological rehabilitation programme
activating seven areas of cognitive functions (memory, atten-
tion, orientation, perception, calculus, executive functioning
and reasoning) with specific tasks. In total, GRADIOR
contains 48 different types of exercises with 2 to 11 levels of
difficulty (see Appendix). For every participant, the GRA-
DIOR treatment will include exercises for all cognitive sub-
domains. At the starting point of the treatment, all the
participants will receive the same set of exercises which will
differ in the level of difficulty for every subdomain based on
the participant’s performance in the preliminary baseline
treatment.
Participants will attend treatment sessions three to
four times per week for 30 min per session. The days
or distribution of treatment sessions during the week
will depend on the availability of each centre and on
the individual availability of participants. The treat-
ment for each participant will be adjusted after
4 months when a midterm assessment will take place.
The treatment can also potentially be adjusted before
this time based on the participant’s performance in
the exercises.
Every exercise in GRADIOR has a duration of 1 min
during which different stimuli are presented to the par-
ticipant who is then asked to provide a specific response
(e.g. point only to a certain group of objects). During
one treatment session, the exercises are randomised for
each subdomain; however, the order of the subdomains
in the treatment is fixed. If the participant does not
complete all exercises on the list in one session, the sub-
sequent session will pick up from where they stopped,
i.e. with tasks for subdomains which are next on the list.
In this way, the programme continues in a loop. The
user does not repeat the same exercises every session,
but only once they have finished the previous set.
ehcoBUTLER: Computer-based psychosocial stimulation
(PSS)
EhcoBUTLER is an e-health platform available via the
Internet, which aims to promote physical and mental
health, social participation, quality of life and personal
wellbeing. EhcoBUTLER is aimed at people with MCI or
mild dementia as well as their carers.
During the first two sessions participants will be
trained to use the system, after which they will use the
platform for 5 h per week or more. The time schedule of
usage of the platform will depend on each participant
and their needs and individual availability. It will be rec-
ommended to participants that they use the platform for
2 h per day. To ensure correct usage of the platform, the
sessions taking place outside of the participants’ homes
will be facilitated by a member of staff. Study coordina-
tors will have access to the data registered by the
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platform to ensure the participation of all users. On the
other hand, the therapist may use the ‘Task List’ function
to propose activities to the participants and subsequently
monitor their accomplishments.
ehcoBUTLER CARE: Combined treatment (GRADIOR +
psychosocial stimulation) (COM)
The group receiving both cognitive rehabilitation and the
psychosocial stimulation treatment will have scheduled
sessions with GRADIOR twice per week for 30 min per ses-
sion and will be advised to use ehcoBUTLER for at least
3 h per week. The treatment sessions with GRADIOR will
be the same as the group only using GRADIOR and the
same procedure will be followed to determine the baseline,
adjustments of treatments and levels of difficulty.
Treatment as usual
Treatment as usual (TAU) is defined as individual care
depending on each participant’s needs, including medi-
cation, social activities, etc. which will not be influenced
by study coordinators or other staff members included
in the study. TAU is usually region-specific due to influ-
ences in a person’s access to services and treatment
availability. Therefore, the outcomes of care for these
participants may vary. Any cognitive intervention,
psychosocial stimulation programmes or activities will
be recorded as potential influences on the outcome mea-
sures. Participants in this group will be put on a waiting
list for the cognitive rehabilitation treatment with
GRADIOR and ehcoBUTLER, and will be offered these
treatment choices once the main trial is finished. TAU is
usually also available to participants in the active treat-
ment groups.
Interventions – modifications
The intermediate testing of cognitive functions, screening,
quality of life and evaluation of emotional state scheduled
after 4 months will provide additional data for treatment
modifications. These tests are important in case of a
scenario where there is a lack of efficacy of the treatment,
observed harms or changes in physical health with an impact
on cognition and emotions, or for any other relevant reason.
Treatment adherence
Interviewers will be trained clinical psychologists or neu-
ropsychologists. All interviewers and staff included in
the study will be provided with a set of guidelines for
communication with participants to ensure that they
have a correct understanding of the treatment sessions
and that effective communication is established between
participants and all staff members. During all GRADIOR
treatment sessions, a member of staff will be present to
provide support to participants, enabling their full
participation in the treatment. However, the member of
staff will not interfere with the treatment. All partici-
pants will be given contact details and times when they
can contact study coordinators regarding any difficulties
experienced or if questions arise during the treatment.
The sessions for both groups receiving cognitive re-
habilitation treatment (GRADIOR and ehcoBUTLER
CARE or combined treatment) will be managed by two
study coordinators independently in each group to avoid
personal bias. The treatment coordinators are trained in
advanced in how to use the GRADIOR programme, in-
cluding setting up and adjusting treatments, and also
have a degree in psychology. Participants receiving treat-
ment in a group setting will be supported during each
session by a separate staff member independent from
the treatment coordinators.
To ensure a high number of participants finish the study
and participate in as many treatment and evaluation ses-
sions as possible, they will be offered different dates of
evaluation. The data collected from participants who pre-
maturely finish the study will be used for partial data ana-
lysis. Interviewers involved in assessment and data
collection will be trained centrally in trial requirements,
ensuring that they have full knowledge of all measurement
scales and know how to correctly administer tests. All in-
terviewers will also receive training in the outcome mea-
sures used during the trial and will comply with the same
administration criteria and standards for every scale and
measurement used. Interviewers will have access to video
guidelines for the correct administration and scoring of all
tests used during the study. During training, interviewers
will learn how to administer each test used in the study
following the video guidelines. Subsequently, to ensure
correct scoring, interviewers will have to score a tested
person featured in the video with a requirement of inter-
rater reliability of κ = 0.80 (between the interviewer in the
training and the interviewer from the video). Study coor-
dinators will be responsible for correct data collection and
administration of all tests by interviewers.
Resources
The RCT relies on human resources and materials available
in the INTRAS Foundation memory clinics in Zamora and
Valladolid, Spain, and is supported by the Department of
Innovation at the Iberian Institute of Research in Psychos-
ciences (IBIP) in Zamora, Spain and the Department of De-
velopment at the INTRAS Foundation in Valladolid,
Spain. The IBIP provides access to neuropsychological
tests, infrastructure, materials and computers, which are
necessary for conducting the study.
The centres involved in the study which do not belong
to INTRAS Foundation will independently provide mate-
rials and human resources necessary for the study. The IN-
TRAS Foundation will provide the centres with the
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GRADIOR software, access to ehcoBUTLER platform,
training of the interviewers and supervision during the in-
terventions to register any incidents or potential problems.
The other collaborating centres are the University of
Salamanca, the Study Institute of Health Sciences of
Castile and Leon health system (IECSCYL) and the
Psychiatry Services and Mental Health Department of
the Care Services in Zamora, Spain.
Ethical approval
The protocol was submitted for ethical approval in May
2017 to the Zamora Provincial Hospital Ethics Committee
and the trial was registered with ISRCTN with a reference
number 15742788. Ethical approval was obtained on 17
May 2017. All participants will obtain written informed
consent about their rights to access the information, data
modification, elimination or correction following the Ley
11/1999 for data protection. All participants will sign the
informed consent form at the beginning of the study and
before any procedure is conducted.
Up until now, no adverse effects of GRADIOR or
ehcoBUTLER have been reported and there are no
known side-effects related to the usage of these pro-
grammes. Should any adverse effects be reported during
the conduct of the study, they will be recorded by the
staff member involved and the appropriate study coord-
inator will be informed.
Outcome measures and hypotheses
Primary outcome measures
GRADIOR stimulates cognitive functioning, which is
reflected in changes in separate cognitive domains.
Outcome measures were selected accordingly. The pri-
mary aim of the study is to determine whether the cogni-
tive rehabilitation programme GRADIOR improves
cognition of people with MCI and PwD in a specific
(GRA) or combined treatment group (COM). Based on
previous research in this area, and our previous experi-
ence with the GRADIOR programme in a clinical setting,
we expect that the two treatment groups using GRADIOR
solely and in combination (COM) will achieve significantly
higher scores in cognitive testing than the TAU group
after 4 and 12 months of treatment. The primary outcome
measure will be an ADASCog Cognitive Subscale [36].
The change in cognitive performance after a period of
4 months and 12 months in comparison with baseline results
will be measured in all study groups using the ADASCog
Cognitive Subscale [36] as the primary outcome, which eval-
uates cognitive performance in memory, praxis, orientation
and language. Additionally, the Spanish version of the Mini-
Mental State Examination (MMSE), consisting of 35 ques-
tions [37], will be used. For a more comprehensive evalu-
ation of a participant’s cognitive profile, we will use a variety
of tests: the Clock Drawing Test [38] for general cognitive
and spatial functioning, WAIS III – Coding digit symbol,
Calculus and Digit Span subtests [39] to evaluate processing
speed, numeric reasoning and working memory respectively,
the Rivermead pattern recognition test [40] for visual
memory, Trail-making tests A and B [41] to monitor motor
functioning, executive functioning and visual-spatial abilities
(part A) and also sustained attention (part B), the
Cambridge Cognitive Examination (CAMCog) –
matrices subtest [42] to examine intellectual ability,
analogic reasoning and abstraction capacity and
Semantic and phonologic verbal fluency [43] and [44]
on animal category and letters P, M and R.
Secondary outcome measures
Changes in quality of life (QoL) scores will be measured
using the EuroQol EQ5D-5 L [45] which assesses quality of
life from five dimensions, and the Luben Social Network
Scale (LSNS) [46] which looks at social engagement, includ-
ing relationships with family and friends. QoL scores will
be compared between all the intervention groups and with
the control group to determine which intervention obtains
the best results and most influences the outcome. We will
compare scores for each intervention group at 4 and
12 months in order to determine at which point in the
treatment the various interventions most influenced quality
of life. All participants will be assessed and compared using
the Geriatric Depression Scale (GDS) [47], a 15-item version
of a self-rating scale, in order to determine which type of
intervention, if any, has an influence on depressive symp-
toms in PwD. Demographic data, activities of daily living
(instrumental – IADL and non-instrumental – ADL), func-
tional aspects and cost-effectiveness will be assessed using
the InterRAI Home Care [48]. The quality of the relation-
ship between the participants and their carers will be
assessed using the Quality of Carer-patient Relationship
(QCPR) questionnaire [49].
As GRADIOR focuses solely on cognitive rehabilitation,
we assume that those participants with dementia receiving
only the GRADIOR treatment will not see improvements
in their quality of life, depressive symptoms, the quality of
their relationships with a carer and/or activities of daily
living after 4 or 12 months.
At the beginning of the study, participants will also re-
ceive the Everyday Technology Use Questionnaire (ETUQ)
[50]. This will assess their perceptions about technology,
difficulties encountered when using technology, and their
degree of experience with technology that might be relevant
for the study.
Carers will also be assessed at the same time as partic-
ipants, whereby we will evaluate the following: their anx-
iety using the State-Trait Anxiety Inventory (STAI) [51],
symptoms of depression with the Beck Depression Inven-
tory II (BDI-II) [52], carer overload using the Caregiver
Burden Interview – Zarit Test [53] and the quality of
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their relationships using the Quality of Carer-patient Re-
lationship (QCPR) questionnaire [49]. We anticipate that
GRADIOR will positively influence carer-outcome mea-
sures, and therefore, we hypothesise that in both inter-
vention groups using GRADIOR, caregiver burden,
anxiety and depression will decrease, and the relation-
ship between the carer and the PwD will improve.
The data collected from the InterRAI Home Care
Assessment will be used to analyse the cost-effectiveness
of the treatment and its impact on health. The economic
evaluation will employ a cost-consequences framework
evaluating the associated costs and outcomes of the
three types of interventions, in comparison to usual care.
The evaluation will also assess the main sources of costs
associated with the interventions. Primary analysis will
be based on the most plausible real-world costs, includ-
ing the cost of the technology and technical progress.
The support costs for GRADIOR and ehcoBUTLER
associated with technical aspects of installation, main-
tenance of hardware and information, as well as commu-
nication technology input related to software and data
management, will be based on data gathered from sites.
This will also include the input of professionals for guid-
ing participants and support provided to participants
throughout the intervention. For a complete list of the
assessment tests used and the time schedule see Tables 2
and 3 respectively.
Analysis
Statistical analysis will be conducted using programme
IBM SPSS v.23. A descriptive analysis of demographic and
personal data will be conducted and results will be com-
pared between all groups. Firstly, an analysis of normality
and homogeneity of the data will be conducted. For nor-
mally distributed data, the repeated measures analysis of
variance (ANOVA) will be used to examine the hypoth-
eses in inter-subject and intra-subject analysis as well as in
their interaction. This will be applied to all outcome mea-
sures in a comparative analysis of the data collected at
from baseline, after 4 months and 12 months of the treat-
ment. In case of non-homogeneous data, non-parametric
methods will be used for analysis (Mann–Whitney U test,
Kruskal-Wallis analysis of variance, Wilcoxon signed-rank
test, calculation of Spearman’s correlation coefficient,
etc.). Bonferroni/Dunnet corrections will be applied dur-
ing post-hoc analysis if needed. The possible effects of
randomisation bias will be analysed using linear-mixed
models including within-group and between-group fac-
tors. The significance level will be set at α = .05.
Effect sizes and their respective standard errors (SE) and
confidence intervals will be estimated as Standardised Mean
Change Index (dMR) for within-group comparisons, and as
Standardised Mean Index difference (dC) for between-group
comparisons, and corrected for small sample sizes [54]:
Exit strategy
A careful exit strategy is required due to the vulnerabil-
ity of the participants, and may be required in the fol-
lowing situations:
1. The situation in which a participant decides to exit
the study prematurely. Reasons for this could vary
from sickness of the participant to lack of time to
participate or even lack of interest in the project, etc.
In this case, a questionnaire to explore the reasons
for exit will be carried out. During the informed
consent process, it will be clearly stated that a
participant can leave at any time with no obligation
to communicate the reasons for leaving. Therefore,
the participant will be invited to voluntarily answer
the questions of the exit questionnaire
It will also be made clear to participants that
leaving the project does not have any implications
for the care that they receive and in a (voluntary)
exit interview staff involved in the project will
make sure that the project has come to a
satisfactory closure and the participant feels
comfortable with the situation
2. The situation in which the study period has come to
an end.
From the beginning of the pilot, it will be made
clear to the participant that the study period is a
maximum of 12 months of treatment and an
additional 12 months of follow-up
From the beginning of the study, it will also be
clearly explained how the study will come to a
close, ensuring participants are aware of the
ending strategy and to prepare them for
transition and closure
If possible, options to continue using the GRADIOR
and/or ehcoBUTLER platform under supervision of a
mentor can be discussed (budget and time permitting)
After closure of the study, the participant is
expected to be able to use the ehcoBUTLER
platform on their own. An information letter can be
offered to answer the most common questions and
to indicate a telephone number in case there are
any questions after the study has ended
Neither study coordinators nor other members of staff
can control or influence the interventions of participants
in the TAU group. Therefore, participants with TAU can
participate by their own initiative on other cognitive re-
habilitation or stimulation programmes outside the compe-
tence of INTRAS Foundation.
Discussion
We will conduct a RCT with a long-term cognitive re-
habilitation intervention and follow-up. This innovative
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RCT aims to determine the influence of a long-term, compu-
terised, cognitive rehabilitation programme on people with
MCI and PwD in comparison to psychosocial stimulation and
TAU. The preliminary usability study will focus on ensuring
that this type of treatment is more convenient and beneficial
for older people, as well as for healthcare professionals.
Limitations of the study are related to the long duration
of the treatment along with the 1 year follow-up. Therefore,
we expect a large number of participants to drop out due
to loss of interest, medical reasons or worsening of a related
health condition, changes in life situation, etc. This poten-
tial dropout rate has been considered in the sample size cal-
culation to ensure the success of the trial. We also foresee
the potential for interviewers and staff to drop out during
the study. In this case, every new member of staff recruited
will be informed about the study and every new interviewer
will undergo the same training in evaluation tools as those
recruited at the start of the study.
For ethical and practical reasons, participants in this
study will not be blinded to the intervention condition.
Table 2 Assessments
Activity/assessment Staff member Time Pre-study Pre-study baseline 2 4 6 8 10 12 16 24
Usability study Interviewer N/A X
Focus group 90
SUS N/A
Consent Form Study coordinator 5 X X X X X X
Inclusion/exclusion criteria Study coordinator N/A X
DSM-5 criteria Interviewer N/A X
Cognitive assessment Interviewer 106
MMSE 20 X X X X X
ADASCog 40 X X X X X
WAIS III: Calculus 5 X X X X X
WAIS III: Digit Span 5 X X X X X
WAIS III: Coding digit symbol 2 X X X X X
TMT A and B 10 X X X X X
Semantic and phonologic verbal fluency 4 X X X X X
CAMCog matrices 5 X X X X X
Clock Drawing Test 10 X X X X X
Pattern recognition test 5 X X X X X
ADL/iADL (InterRAI HC) Interviewer N/A X X X X X
Quality of life Interviewer 20
EQ5D-5 L 5 X X X X X
LSNS (Luben) 15 X X X X X
Mood Interviewer 15
GDS 15 X X X X X
Patient-carer relationship N/A
QCPR X X X X X
Technological assessment Interviewer N/A
ETUQ X
Randomisation Study coordinator N/A X
Treatment (group-specific) Study coordinator N/A X X X X X X
Termination Form Study coordinator N/A As needed throughout the study
Adverse Event Form Study coordinator N/A As needed throughout the study
Progress notes All N/A X X X X
Communication log All N/A Every phone or in-person contact outside of regular visit
ADASCog Alzheimer’s Disease Assessment Scale – Cognitive Subscale, ADL activities of daily living, CAMCog Cambridge Cognition Examination, EQ5d-5 L EuroQoL 5
dimensions, 5 levels, ETUQ Everyday Technology Use Questionnaire, GDS Geriatric Depression Scale, LSNS Luben Social Network Scale, MMSE Mini Mental State
Examination, N/A not applicable, QCPR Quality of Patient-carer Relationship, SUS System Usability Scale, TMT Trail-making test
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Huntley et al. [55] recommend conducting single-blinded
psychosocial intervention RCTs to minimise other factors,
such as socialisation, when using the TAU control group
(e.g. patient blinded and assessor blinded, but not therapist
blinded). However, this is difficult to apply in practice due
to ethical reasons. Therefore, we are conducting a single-
blinded RCT with four parallel groups. In this study, all in-
terviewers will be blinded to participants’ treatment alloca-
tion. Study coordinators who will manage and adjust the
GRADIOR treatments of all participants will do so only
based on data obtained from the programme and manage
this under a participant’s code (Fig. 1 and Additional file 1).
STUDY PERIOD
Enrolment Allocation Post-allocation
TIMEPOINT** -3 moths 0 4 12 16 24
ENROLMENT:
Eligibility screen X
Informed consent X X
Usability study X
Allocation X
INTERVENTIONS:
GRADIOR
ehcoBUTLER
Combined 
treatment
Treatment as usual
ASSESSMENTS:
MMSE X X X X X
ADASCog X X X X X
WAIS III: Calculus X X X X X
WAIS III: Digit span X X X X X
WAIS III: Coding 
digit symbol
X X X X X
TMT A and B X X X X X
Semantic and 
phonologic verbal 
fluency
X X X X X
CAMCog matrices X X X X X
Clock Drawing 
Test
X X X X X
Pattern recognition 
test 
X X X X X
ADL/iADL (InterRAI 
HC)
X X X X X
EQ5D-5L X X X X X
LSNS (LUBEN) X X X X X X
GDS X X X X X X
QCPR X X X X X X
ETUQ X
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure. Recommended items to address in a clinical trial
protocol and related documents
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Trial status
The RCT trial on the effectiveness of GRADIOR started
on 1 September 2016 and will be recruiting participants
from 1 September 2017. The end of the trial is foreseen
for 1 September 2019.
Appendix
Additional file
Additional file 1: SPIRIT Checklist. Recommended items to address in a
clinical trial protocol and related documents. (DOC 120 kb)
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